JP5475992B2 - 多剤リガンド結合体 - Google Patents

多剤リガンド結合体 Download PDF

Info

Publication number
JP5475992B2
JP5475992B2 JP2008527205A JP2008527205A JP5475992B2 JP 5475992 B2 JP5475992 B2 JP 5475992B2 JP 2008527205 A JP2008527205 A JP 2008527205A JP 2008527205 A JP2008527205 A JP 2008527205A JP 5475992 B2 JP5475992 B2 JP 5475992B2
Authority
JP
Japan
Prior art keywords
linker
drug delivery
drug
conjugate
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008527205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504784A (ja
JP2009504784A5 (enExample
Inventor
ヴラホフ，イオンチョ，ラドスラヴォフ
リーモン，クリストファー，ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of JP2009504784A publication Critical patent/JP2009504784A/ja
Publication of JP2009504784A5 publication Critical patent/JP2009504784A5/ja
Application granted granted Critical
Publication of JP5475992B2 publication Critical patent/JP5475992B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2008527205A 2005-08-19 2006-08-18 多剤リガンド結合体 Expired - Fee Related JP5475992B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70995005P 2005-08-19 2005-08-19
US60/709,950 2005-08-19
US78755806P 2006-03-30 2006-03-30
US60/787,558 2006-03-30
PCT/US2006/032561 WO2007022494A2 (en) 2005-08-19 2006-08-18 Multi-drug ligand conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012261698A Division JP2013079248A (ja) 2005-08-19 2012-11-29 多剤リガンド結合体

Publications (3)

Publication Number Publication Date
JP2009504784A JP2009504784A (ja) 2009-02-05
JP2009504784A5 JP2009504784A5 (enExample) 2009-10-08
JP5475992B2 true JP5475992B2 (ja) 2014-04-16

Family

ID=37654952

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008527205A Expired - Fee Related JP5475992B2 (ja) 2005-08-19 2006-08-18 多剤リガンド結合体
JP2012261698A Pending JP2013079248A (ja) 2005-08-19 2012-11-29 多剤リガンド結合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012261698A Pending JP2013079248A (ja) 2005-08-19 2012-11-29 多剤リガンド結合体

Country Status (11)

Country Link
US (3) US8465724B2 (enExample)
EP (2) EP2374480A3 (enExample)
JP (2) JP5475992B2 (enExample)
KR (2) KR101364912B1 (enExample)
CN (2) CN103893779A (enExample)
AU (1) AU2006279304A1 (enExample)
BR (1) BRPI0615354A2 (enExample)
CA (1) CA2617660C (enExample)
ES (1) ES2468240T3 (enExample)
RU (2) RU2470668C2 (enExample)
WO (1) WO2007022494A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3831382A1 (de) * 1988-09-15 1990-04-12 Hoechst Ag Verfahren zur herstellung von 2-alkoxy-benzolsulfonamid-verbindungen
ATE427948T1 (de) * 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
EP2517730A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
US8288557B2 (en) * 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
JP5289935B2 (ja) * 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
US8465724B2 (en) 2005-08-19 2013-06-18 Endocyte, Inc. Multi-drug ligand conjugates
EP2037966A2 (en) 2006-05-11 2009-03-25 Ghent University Sialoadhesin-related compositions and methods
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
ES2704199T3 (es) 2007-02-16 2019-03-14 Vergell Medical S A Profármacos de doble acción
US9216228B2 (en) 2007-02-16 2015-12-22 KTB Tumorforschungsgesellschaft MBM Receptor and antigen targeted prodrug
CN101678124A (zh) 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
DK2146944T3 (da) 2007-04-11 2014-02-03 Merck & Cie Fremgangsmåde til fremstillingen af 18f-mærkede folater
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009012109A2 (en) 2007-07-13 2009-01-22 Emory University Cyanine-containing compounds for cancer imaging and treatment
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
ES3029483T3 (en) 2008-09-17 2025-06-24 Endocyte Inc Folate receptor binding conjugates of antifolates
WO2010045584A1 (en) * 2008-10-17 2010-04-22 Endocyte, Inc. Folate targeting of nucleotides
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
EP2464654B1 (en) 2009-08-10 2014-10-08 UCL Business PLC Thiol protecting group
JP5780961B2 (ja) * 2009-09-07 2015-09-16 ニプロパッチ株式会社 経皮吸収型製剤
WO2011069116A1 (en) * 2009-12-04 2011-06-09 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CA2812543A1 (en) * 2010-09-27 2012-04-12 Endocyte, Inc. Folate conjugates for treating inflammation of the eye
CA2822447C (en) * 2010-12-23 2018-05-01 Alkermes Pharma Ireland Limited Multi-api loading prodrugs
WO2012090104A1 (en) * 2010-12-31 2012-07-05 Kareus Therapeutics, Sa Methods and compositions for designing novel conjugate therapeutics
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
MY171561A (en) 2012-11-15 2019-10-18 Endocyte Inc Conjugates for treating diseases caused by psma expressing cells
SI2956173T1 (sl) 2013-02-14 2017-06-30 Bristol-Myers Squibb Company Spojine tubulizina, postopki pridobivanja in uporaba
GEP20237479B (en) 2013-10-18 2023-03-27 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3069147A4 (en) 2013-11-14 2017-10-11 Endocyte, Inc. Compounds for positron emission tomography
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
WO2016089879A1 (en) * 2014-12-01 2016-06-09 Endocyte, Inc. Conjugates of garftase inhibitors
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CN104569416B (zh) * 2015-01-22 2016-04-13 中国农业大学 检测稻曲菌素b的方法及其专用酶联免疫试剂盒
WO2016148674A1 (en) * 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases
WO2016183131A1 (en) 2015-05-11 2016-11-17 Purdue Research Foundation Ligand ionophore conjugates
AU2016305703B2 (en) 2015-08-11 2019-07-25 Coherent Biopharma I, Limited Multi-ligand drug conjugates and uses thereof
JOP20170053B1 (ar) 2016-03-02 2021-08-17 Eisai Randd Man Co Ltd مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
JP7027325B2 (ja) 2016-03-16 2022-03-01 パーデュー・リサーチ・ファウンデイション 炭酸無水酵素ｉｘを標的とする薬剤および方法
WO2017161144A1 (en) * 2016-03-16 2017-09-21 Endocyte, Inc. Carbonic anhydrase ix inhibitor conjugates and uses thereof
EP3445402A4 (en) * 2016-04-21 2019-12-11 The Board Of Regents Of The University Of Texas System METHOD AND COMPOSITIONS FOR DETECTING ANEURYSMS
WO2017205661A1 (en) * 2016-05-25 2017-11-30 Purdue Research Foundation Method of treating cancer by targeting myeloid-derived suppressor cells
WO2018089481A1 (en) * 2016-11-08 2018-05-17 Mallinckrodt Llc Mitomycin c prodrug liposome formulations and uses thereof
SG11202010217YA (en) 2018-04-17 2020-11-27 Endocyte Inc Methods of treating cancer
MX2021002569A (es) 2018-09-06 2021-06-08 Cidara Therapeutics Inc Composiciones y metodos para el tratamiento de infecciones virales.
US12473265B2 (en) 2019-05-20 2025-11-18 Endocyte, Inc. Methods for preparing PSMA conjugates
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
CN114728937A (zh) * 2019-09-09 2022-07-08 奇达拉治疗公司 用于治疗呼吸道合胞病毒的组合物及方法
JP2020117509A (ja) * 2020-03-12 2020-08-06 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 疾患を処置するためのコンジュゲート
JP2024537396A (ja) * 2021-10-14 2024-10-10 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド ＥｐｈＡ２の二環式ペプチドリガンド及びそのコンジュゲート

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2515483A (en) 1946-08-10 1950-07-18 Merck & Co Inc Diacylated pteroic acid and process for preparing same
US2816110A (en) 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US3392173A (en) 1964-03-09 1968-07-09 Lilly Co Eli Novel acyl derivatives of desacetyl-vincaleukoblastine and processes for their preparation
US3387001A (en) 1964-10-19 1968-06-04 Lilly Co Eli Novel aminoacyl esters of desacetyl vincaleukoblastine
US4203898A (en) 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4166810A (en) 1978-04-20 1979-09-04 Eli Lilly And Company Derivatives of 4-desacetyl VLB C-3 carboxyhydrazide
US4337339A (en) 1979-04-30 1982-06-29 Baker Instruments Corp. Process for preparation of folic acid derivatives
US4639456A (en) 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US5140104A (en) 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US4770994A (en) * 1982-07-30 1988-09-13 Abbott Laboratories Determination of carbohydrate acceptors
DE116208T1 (de) 1982-12-07 1985-02-28 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Mitomycin-analoge.
GR81790B (enExample) 1983-04-29 1984-12-12 Omnichem Sa
US4866180A (en) 1984-02-24 1989-09-12 Bristol-Myers Company Amino disulfide thiol exchange products
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体，その製造法および抗腫瘍剤
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
IL82579A0 (en) 1986-05-27 1987-11-30 Lilly Co Eli Immunoglobulin conjugates
US4801688A (en) 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
EP0280741B1 (en) 1986-08-29 1994-12-07 Kyowa Hakko Kogyo Kabushiki Kaisha Mitomycin derivatives
US5006652A (en) 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
US5094849A (en) 1988-08-08 1992-03-10 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
EP0457875A4 (en) 1989-11-13 1993-03-03 Xoma Corporation Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5998603A (en) 1994-09-29 1999-12-07 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analogs, and oligomers thereof
ES2171392T3 (es) 1990-08-29 2002-09-16 Ct Hospitalier Regional De Nan Poliligandos de proteina unidos a un nucleo de proteina estable.
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5378696A (en) 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5194447A (en) 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5169851A (en) 1991-08-07 1992-12-08 American Home Products Corporation Rapamycin analog as immunosuppressants and antifungals
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5159079A (en) 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
ES2176245T3 (es) 1993-04-23 2002-12-01 Wyeth Corp Anticuerpos de ramapicinas de ciclo abierto.
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
IL112873A (en) 1994-03-08 2005-03-20 Wyeth Corp Rapamycin-fkbp12 binding proteins, their isolation and their use
US6171859B1 (en) 1994-03-30 2001-01-09 Mitokor Method of targeting conjugate molecules to mitochondria
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5547668A (en) 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6030941A (en) 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
ATE365562T1 (de) 1996-05-03 2007-07-15 Immunomedics Inc Zielgerichtete kombinations-immuntherapie für krebs
DE19621133A1 (de) 1996-05-24 1997-11-27 Boehringer Mannheim Gmbh Bestimmungsverfahren mit oligomerisierten Rezeptoren
CA2264592C (en) * 1996-08-27 2012-02-21 University Of Utah Research Foundation Bioconjugates and delivery of bioactive agents
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US6291673B1 (en) 1997-10-17 2001-09-18 Purdue Research Foundation Folic acid derivatives
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
CN100512879C (zh) 1999-04-23 2009-07-15 阿尔萨公司 用于脂质体中的有可裂解键的缀合物
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
AUPQ071299A0 (en) 1999-06-02 1999-06-24 Access Pharmaceuticals Australia Pty Limited Vitamin directed dual targeting therapy
EP1212120A2 (en) * 1999-09-07 2002-06-12 Conjuchem, Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents
AU4243400A (en) * 1999-10-15 2001-04-30 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging agents and as antitumor agents
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
CN102805868A (zh) 2000-03-31 2012-12-05 普渡研究基金会 用配体-免疫原缀合物治疗的方法
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
US6290929B1 (en) 2000-07-28 2001-09-18 The Procter & Gamble Company Cancer treatment
DK1318837T3 (da) 2000-08-11 2005-01-10 Wyeth Corp Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
ES2313983T3 (es) 2000-09-19 2009-03-16 Wyeth Esteres hidrosolubles de rapamicina.
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
EP2316976A1 (en) 2000-11-28 2011-05-04 Wyeth LLC Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US20020168737A1 (en) * 2001-01-24 2002-11-14 Cornish Virginia W. Binding and catalysis screen for high throughput determination of protein function using chemical inducers of dimerization
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
JP2004533226A (ja) 2001-04-02 2004-11-04 ワイス Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
JP2004532888A (ja) 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
US20040018203A1 (en) 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
DE60206512T2 (de) 2001-08-22 2006-06-22 Wyeth Rapamycin 29-enole
MXPA04001523A (es) 2001-08-22 2004-05-31 Wyeth Corp Dialdehidos de rapamicina.
JP2005523878A (ja) 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション リガンド・免疫原物質複合体を用いた処置方法
GR1004163B (el) 2001-11-01 2003-02-21 Πολυκυκλικα παραγωγα τροποποιησης των οπτικων ιδιοτητων και των ιδιοτητων αντοχης στο πλασμα των πολυμερων λιθογραφιας
US6595757B2 (en) * 2001-11-27 2003-07-22 Kuei-Hsien Shen Air compressor control system
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US7000695B2 (en) 2002-05-02 2006-02-21 Halliburton Energy Services, Inc. Expanding wellbore junction
ATE448799T1 (de) 2002-05-06 2009-12-15 Endocyte Inc Folatrezeptor gerichtete bildgebende konjugate
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
EP1504010B1 (en) 2002-05-15 2009-03-25 Endocyte, Inc. Vitamin-mitomycin conjugates
EP1523493B1 (de) 2002-07-09 2013-09-04 Dömling, Alexander Neue tubulysinanaloga
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
CA2501752A1 (en) 2002-10-10 2004-04-22 Wyeth Compositions, organisms and methodologies employing a novel human kinase
EP1578197A4 (en) 2002-11-21 2006-05-17 Wyeth Corp COMPOSITION AND METHOD FOR THE TREATMENT OF LUPUS NEPHRITIS
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
EP2517730A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
AR042938A1 (es) 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
WO2004101803A2 (en) 2003-05-12 2004-11-25 Wyeth Holdings Corporation Process for producing anticancer agent ll-d45042
CA2528173A1 (en) 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
RU2339639C2 (ru) 2003-08-07 2008-11-27 Уайт Региоселективный синтез cci-779
EP1737879B1 (en) 2004-04-19 2012-10-10 Archemix LLC Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
JP5289935B2 (ja) 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
AU2006230219A1 (en) 2005-03-30 2006-10-05 Endocyte, Inc. Method for cancer prognosis using cellular folate vitamin receptor quantification
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
EP2382995A3 (en) 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
US8465724B2 (en) 2005-08-19 2013-06-18 Endocyte, Inc. Multi-drug ligand conjugates
JP2009518289A (ja) 2005-11-21 2009-05-07 メディバス エルエルシー 高分子の送達用ポリマー粒子および使用方法
PE20080102A1 (es) 2006-05-25 2008-02-11 Bristol Myers Squibb Co Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN101678124A (zh) 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
WO2010045598A2 (en) 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US20120258905A1 (en) 2009-12-23 2012-10-11 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation

Also Published As

Publication number Publication date
JP2013079248A (ja) 2013-05-02
BRPI0615354A2 (pt) 2011-05-17
RU2470668C2 (ru) 2012-12-27
US20080248052A1 (en) 2008-10-09
CA2617660C (en) 2014-03-25
US20130184435A1 (en) 2013-07-18
WO2007022494A3 (en) 2007-09-07
KR20130113543A (ko) 2013-10-15
CA2617660A1 (en) 2007-02-22
KR101364912B1 (ko) 2014-02-21
KR20080041223A (ko) 2008-05-09
AU2006279304A1 (en) 2007-02-22
WO2007022494A2 (en) 2007-02-22
RU2008110495A (ru) 2009-09-27
EP2374480A3 (en) 2013-05-01
JP2009504784A (ja) 2009-02-05
US8465724B2 (en) 2013-06-18
US20140058064A1 (en) 2014-02-27
ES2468240T3 (es) 2014-06-16
CN103893778A (zh) 2014-07-02
RU2012136587A (ru) 2014-03-10
EP1948241B1 (en) 2014-03-05
EP2374480A2 (en) 2011-10-12
CN103893779A (zh) 2014-07-02
EP1948241A2 (en) 2008-07-30

Similar Documents

Publication Publication Date Title
JP5475992B2 (ja) 多剤リガンド結合体
JP2009504783A (ja) ビンカアルカロイド、類似体および誘導体のリガンド結合体
JP5690589B2 (ja) 親水性スペーサーリンカーを含有する結合体
TWI492750B (zh) 維生素-受體結合性藥物輸送共軛物、醫藥組合物、用途及製備方法
US9555139B2 (en) Binding ligand linked drug delivery conjugates of tubulysins
CN100381177C (zh) 维生素受体结合递药缀合物
AU2013204293A1 (en) Multi-drug ligand conjugates
HK1179517A (en) Vitamin receptor binding drug delivery conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120824

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130619

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140207

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees